141 related articles for article (PubMed ID: 28893679)
1. Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs.
Atzeni F; Carletto A; Foti R; Sebastiani M; Panetta V; Salaffi F; Bonitta G; Iannone F; Gremese E; Govoni M; Marchesoni A; Favalli EG; Gorla R; Ramonda R; Sarzi-Puttini P; Ferraccioli G; Lapadula G;
Joint Bone Spine; 2018 Jul; 85(4):455-459. PubMed ID: 28893679
[TBL] [Abstract][Full Text] [Related]
2. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.
Atzeni F; Sarzi-Puttini P; Sebastiani M; Panetta V; Salaffi F; Iannone F; Carletto A; Foti R; Gremese E; Govoni M; Marchesoni A; Favalli E; Gorla R; Ramonda R; Ferraccioli G; Lapadula G;
Clin Exp Rheumatol; 2019; 37(4):649-655. PubMed ID: 30767865
[TBL] [Abstract][Full Text] [Related]
3. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
[TBL] [Abstract][Full Text] [Related]
4. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database.
Scirè CA; Caporali R; Sarzi-Puttini P; Frediani B; Di Franco M; Tincani A; Sinigaglia L; Sfriso P; Tirri R; Bellis E; Delsante G; Porru G; Salaffi F; Giuggioli D; Rossini M; Todoerti M; Bazzichi L; Govoni M; Gerli R; Raschetti R; Minisola G; Montecucco C; Todesco S;
Clin Exp Rheumatol; 2013; 31(6):857-63. PubMed ID: 23981363
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
6. Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study.
Krajewski F; Andras L; Pereira-Gillion C; Goupille P; Salliot C
Joint Bone Spine; 2019 Nov; 86(6):761-767. PubMed ID: 31326602
[TBL] [Abstract][Full Text] [Related]
7. Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.
Favalli EG; Selmi C; Becciolini A; Biggioggero M; Ariani A; Santilli D; Fusaro E; Parisi S; Massarotti M; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2017 Jun; 69(6):867-874. PubMed ID: 27696735
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Drug Survival of Anti-Tumor Necrosis Factor α Therapies in Patients With Spondyloarthritis: Analysis From the Thai Rheumatic Disease Prior Authorization Registry.
Chiowchanwisawakit P; Katchamart W; Osiri M; Narongroeknawin P; Chevaisrakul P; Kitumnuaypong T; Siripaitoon B; Louthrenoo W
J Clin Rheumatol; 2019 Jan; 25(1):9-15. PubMed ID: 29517554
[TBL] [Abstract][Full Text] [Related]
9. Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs.
Scagnellato L; Collesei A; Doria A; Cozzi G; Lorenzin M; Atzeni F; Bugatti S; Caporali R; Cauli A; Conti F; Corrado A; Carletto A; Chimenti MS; Foti R; Frediani B; Gerli R; Gorla R; Govoni M; Gremese E; Guiducci S; Iagnocco A; Iannone F; Parisi S; Rossini M; Salaffi F; Santo L; Sarzi Puttini P; Sebastiani M; Semerano A; Ferraccioli G; Lapadula G; Ramonda R;
Clin Exp Rheumatol; 2024 Jan; 42(1):104-114. PubMed ID: 37650298
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
[TBL] [Abstract][Full Text] [Related]
11. Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.
Sepriano A; Ramiro S; van der Heijde D; Ávila-Ribeiro P; Fonseca R; Borges J; Teixeira L; Carvalho PD; Cerqueira M; Neves J; Meirinhos T; Barcelos A; Sequeira G; Salvador MJ; Canas da Silva J; Santos H; Bernardes M; Vieira-Sousa E; Canhão H; Branco JC; Pimentel-Santos F; Landewé R
Arthritis Rheumatol; 2016 Nov; 68(11):2671-2679. PubMed ID: 27273894
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Infectious Adverse Events in Patients With Rheumatoid Arthritis and Spondyloarthritis on Biologic Drugs-Data From the Brazilian Registry for Biologics Monitoring.
Cecconi M; Ranza R; Titton DC; Moraes JCB; Bertolo M; Bianchi W; Brenol C; Carvalho HM; de Castro GRW; Costa IP; Cunha MFL; Duarte Â; Fernandes V; Freire M; Louzada-Junior P; Macieira JC; Miranda JRS; Pereira IA; Pinheiro GRC; Stadler B; Toledo RA; Valim V; Descalzo MA; Pinto RMC; Laurindo I
J Clin Rheumatol; 2020 Mar; 26(2):73-78. PubMed ID: 32073519
[TBL] [Abstract][Full Text] [Related]
13. The clinical importance of the thyroid nodules during anti-tumor necrosis factor therapy in patients with axial spondyloarthritis.
Terlemez R; Akgün K; Palamar D; Boz S; Sarı H
Clin Rheumatol; 2017 May; 36(5):1071-1076. PubMed ID: 28357602
[TBL] [Abstract][Full Text] [Related]
14. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
Beukelman T; Xie F; Chen L; Horton DB; Lewis JD; Mamtani R; Mannion MM; Saag KG; Curtis JR
Ann Rheum Dis; 2018 Jul; 77(7):1012-1016. PubMed ID: 29440001
[TBL] [Abstract][Full Text] [Related]
15. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
16. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
Fiorentino D; Ho V; Lebwohl MG; Leite L; Hopkins L; Galindo C; Goyal K; Langholff W; Fakharzadeh S; Srivastava B; Langley RG
J Am Acad Dermatol; 2017 Nov; 77(5):845-854.e5. PubMed ID: 28893407
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR).
Westhovens I; Lories RJ; Westhovens R; Verschueren P; de Vlam K
Clin Exp Rheumatol; 2014; 32(1):71-6. PubMed ID: 24295201
[TBL] [Abstract][Full Text] [Related]
18. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
19. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
[TBL] [Abstract][Full Text] [Related]
20. Predictive clinical-genetic model of long-term non-response to tumor necrosis factor-alpha inhibitor therapy in spondyloarthritis.
Polo Y La Borda J; Campos J; Sanz J; Andréu JL; Mulero J; Sánchez A
Int J Rheum Dis; 2019 Aug; 22(8):1529-1537. PubMed ID: 31119895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
